Inovio Pharmaceuticals Inc vs KeyCorp — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while KeyCorp trades at $22.7 (market cap $24.32B). The key difference: KeyCorp is far larger — about 309.6× Inovio Pharmaceuticals Inc's market cap, and KeyCorp pays a 3.61% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | KEY | |
|---|---|---|
Market Cap | $78.55M | $24.32B |
Sector | Health | Financials |
52-Week High | $2.87 | $23.99 |
52-Week Low | $0.66 | $16.78 |
Enterprise Value | $49.56M | — |
Dividend Yield | — | 3.61% |
Trailing returns across standard periods
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →